Recent Updates
Recently added Catalysts
HOWL Positive Sentiment

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Friday, November 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Werewolf Therapeutics has presented preliminary data from its Phase 1/1b clinical trial for WTX-124, an interleukin 2 INDUKINE molecule. The trial targets patients with advanced or metastatic solid tumors. This data, showcasing the proof of mechanism, is being shared at the Society for Immunotherapy of Cancer's 38th Annual Meeting.
Price reaction · baseline $2.15 (2023-11-02 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close · peak
+47.4%
day 1
+40.9%
day 3
+27.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Preliminary data shows promising results for WTX-124.
  • The trial is part of an innovative approach to cancer treatment.
  • Presentation at a significant conference highlights the importance of the findings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors

Full Press Release Details

WATERTOWN, Mass., November 3, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124×2101. This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors. The preliminary data will be presented today at the Society for Immunotherapy of Cancer’s (SITC) 38 th Annual Meeting in San Diego, California.

Frequently Asked Questions

What is WTX-124?

WTX-124 is an interleukin 2 INDUKINE molecule developed by Werewolf Therapeutics.

What type of trial is being conducted for WTX-124?

A Phase 1/1b clinical trial is ongoing for WTX-124, focusing on advanced solid tumors.

Where was the preliminary data presented?

The data was presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting.

What is the goal of the WTX-124 trial?

The trial aims to establish proof of mechanism for WTX-124 in cancer treatment.

ShareAdd on Google
Tags: HOWL Viatris Investor Conferences Healthcare Werewolf Therapeutics WTX-124 Phase 1 trial cancer treatment SITC 2023
Last updated: Nov 3, 2023

Biotech snapshot

Cash runway
$22M liquidity · $0M/mo burn
Low dilution risk
Lead asset
WTX-330Phase 1
Advanced or Metastatic Solid Tumors →

Catalyst track record

+25%
best trade around HOWL's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for HOWL.

See every catalyst's timing & PoA →